Editas Medicine - EDIT Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $15.00
Forecasted Upside: 173.22%
Number of Analysts: 9
Breakdown:
0 Sell Ratings
4 Hold Ratings
5 Buy Ratings
0 Strong Buy Ratings

^$5.49 As of 04/19/2024 01:00 AM ET

▼ -0.06 (-1.08%)

1 month | 3 months | 12 months

Get New Editas Medicine Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for EDIT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EDIT

^$15.00

▲ +173.22% Upside Potential

This price target is based on 9 analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is $15.00, with a high forecast of $20.00 and a low forecast of $9.00. The average price target represents a 173.22% upside from the last price of $5.49.

Current Consensus is Moderate Buy

The current consensus among 9 investment analysts is to moderate buy stock in Editas Medicine. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
5 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

10/27/2022

0 strong buy ratings
5 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

1/25/2023

0 strong buy ratings
5 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

4/25/2023

0 strong buy ratings
5 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

7/24/2023

0 strong buy ratings
5 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

10/22/2023

0 strong buy ratings
5 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

1/20/2024

0 strong buy ratings
5 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

3/20/2024

0 strong buy ratings
5 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

4/19/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/29/2024	Citigroup	Boost Target	Buy ➝ Buy	$11.00 ➝ $16.00	Low
2/29/2024	Barclays	Boost Target	Equal Weight ➝ Equal Weight	$10.00 ➝ $11.00	Low
2/27/2024	JPMorgan Chase & Co.	Boost Target	Neutral ➝ Neutral	$8.00 ➝ $9.00	Low
12/12/2023	Truist Financial	Boost Target	Buy ➝ Buy	$15.00 ➝ $20.00	Low
10/24/2023	Citigroup	Upgrade	Neutral ➝ Buy	$11.00	Low
10/18/2023	JPMorgan Chase & Co.	Upgrade	Underweight ➝ Neutral	$8.00	Low
10/17/2023	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral		Low
9/28/2023	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$9.00 ➝ $17.00	Low
9/13/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$14.00	Low
8/29/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$14.00	Low
8/3/2023	Oppenheimer	Reiterated Rating	Market Perform ➝ Market Perform	$12.00	Low
8/2/2023	Chardan Capital	Lower Target	Buy ➝ Buy	$22.00 ➝ $19.00	Low
6/12/2023	Raymond James	Upgrade	Market Perform ➝ Outperform	$17.00	Low
2/23/2023	Credit Suisse Group	Boost Target	Neutral	$13.00 ➝ $15.00	Low
2/23/2023	Royal Bank of Canada	Lower Target	Sector Perform	$14.00 ➝ $10.00	Low
2/23/2023	Chardan Capital	Lower Target	Buy	$35.00 ➝ $22.00	Low
2/23/2023	Wells Fargo & Company	Lower Target		$36.00 ➝ $30.00	Low
1/31/2023	Cantor Fitzgerald	Initiated Coverage	Overweight	$15.00	Low
1/24/2023	Morgan Stanley	Lower Target	Underweight	$8.00 ➝ $7.00	Low
1/23/2023	SVB Leerink	Boost Target	Market Perform	$6.00 ➝ $7.00	Low
1/10/2023	SVB Leerink	Lower Target	Market Perform	$7.00 ➝ $6.00	Low
1/4/2023	Wells Fargo & Company	Lower Target	Overweight	$50.00 ➝ $36.00	Low
12/13/2022	Citigroup	Initiated Coverage	Neutral	$11.00	Low
12/6/2022	Credit Suisse Group	Reiterated Rating	Neutral	$13.00	Low
11/21/2022	Evercore ISI	Lower Target		$8.00	Low
11/18/2022	Bank of America	Lower Target	Neutral	$18.00 ➝ $15.00	Low
11/18/2022	Morgan Stanley	Lower Target	Underweight	$10.00 ➝ $8.00	Low
11/18/2022	Royal Bank of Canada	Lower Target	Sector Perform	$32.00 ➝ $14.00	Low
11/18/2022	Truist Financial	Lower Target	Buy	$80.00 ➝ $35.00	Low
11/18/2022	Robert W. Baird	Lower Target	Outperform	$25.00 ➝ $18.00	Low
11/17/2022	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$25.00 ➝ $13.00	Low
11/17/2022	Chardan Capital	Lower Target	Buy	$43.00 ➝ $35.00	Low
11/17/2022	Oppenheimer	Downgrade	Outperform ➝ Market Perform	$28.00 ➝ $12.00	Low
11/17/2022	SVB Leerink	Lower Target	Market Perform	$14.00 ➝ $7.00	Low
11/8/2022	Morgan Stanley	Lower Target	Underweight	$15.00 ➝ $10.00	Low
11/3/2022	Royal Bank of Canada	Lower Target	Sector Perform	$40.00 ➝ $32.00	Low
11/3/2022	Robert W. Baird	Lower Target	Outperform	$30.00 ➝ $25.00	Low
11/3/2022	SVB Leerink	Lower Target	Market Perform	$14.00 ➝ $12.00	Low
11/2/2022	Chardan Capital	Lower Target	Buy	$60.00 ➝ $43.00	Low
9/29/2022	Bank of America	Initiated Coverage	Neutral	$18.00	Low
8/4/2022	Barclays	Boost Target	Equal Weight	$16.00 ➝ $17.00	Low
5/24/2022	The Goldman Sachs Group	Lower Target	Sell	$10.00 ➝ $8.00	Medium
5/5/2022	Oppenheimer	Lower Target		$55.00 ➝ $28.00	High
4/18/2022	Robert W. Baird	Lower Target		$44.00 ➝ $33.00	High
4/12/2022	Morgan Stanley	Boost Target	Underweight	$16.00 ➝ $17.00	Medium
2/25/2022	Barclays	Lower Target		$39.00 ➝ $18.00	High
2/25/2022	Chardan Capital	Lower Target	Buy	$75.00 ➝ $60.00	High
2/25/2022	Oppenheimer	Lower Target	Outperform	$80.00 ➝ $55.00	High
2/25/2022	SVB Leerink	Lower Target	Market Perform	$41.00 ➝ $27.00	High
2/11/2022	Evercore ISI	Downgrade	Hold	$15.00	High
1/6/2022	Morgan Stanley	Lower Target	Underweight	$37.00 ➝ $24.00	Low
10/20/2021	Robert W. Baird	Reiterated Rating	Buy		Medium
10/19/2021	SVB Leerink	Initiated Coverage	Market Perform	$41.00	Medium
9/30/2021	Chardan Capital	Reiterated Rating	Buy	$75.00	Medium
9/30/2021	Stifel Nicolaus	Lower Target	Hold	$65.00 ➝ $46.00	High
9/23/2021	Stifel Nicolaus	Initiated Coverage	Hold	$65.00	High
9/9/2021	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$42.00 ➝ $80.00	Medium
8/9/2021	Truist Financial	Upgrade	Buy	$80.00	Low
8/5/2021	Evercore ISI	Upgrade	Underperform ➝ Outperform	$20.00 ➝ $60.00	High
7/7/2021	Chardan Capital	Reiterated Rating	Buy		Medium
5/10/2021	Morgan Stanley	Lower Target	Underweight	$40.00 ➝ $37.00	High
5/3/2021	Royal Bank of Canada	Initiated Coverage	Sector Perform	$40.00	High
4/16/2021	The Goldman Sachs Group	Initiated Coverage	Sell	$20.00	High
3/22/2021	Credit Suisse Group	Initiated Coverage	Outperform	$58.00	High
3/8/2021	Barclays	Reiterated Rating	Overweight ➝ Equal Weight	$46.00	Medium
3/2/2021	Morgan Stanley	Lower Target	Underweight	$45.00 ➝ $40.00	Medium
3/1/2021	Barclays	Downgrade	Overweight ➝ Equal Weight	$46.00	Low
2/28/2021	JPMorgan Chase & Co.	Reiterated Rating	Sell	$30.00	Low
2/26/2021	Truist Financial	Downgrade	Buy ➝ Hold	$45.00	Low
2/25/2021	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$30.00	Medium
2/10/2021	Chardan Capital	Boost Target	Buy	$55.00 ➝ $77.00	Low
1/20/2021	JPMorgan Chase & Co.	Reiterated Rating	Hold		Low
1/19/2021	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight	$64.00 ➝ $45.00	Low
1/13/2021	Wells Fargo & Company	Boost Target	Overweight	$69.00 ➝ $86.00	Medium
1/7/2021	Raymond James	Downgrade	Outperform ➝ Market Perform		N/A
12/16/2020	Morgan Stanley	Boost Target	Equal Weight	$30.00 ➝ $64.00	Low
12/10/2020	Wells Fargo & Company	Upgrade	Equal Weight ➝ Overweight	$28.00 ➝ $69.00	High
11/11/2020	Morgan Stanley	Lower Target	Equal Weight	$31.00 ➝ $30.00	High
11/6/2020	Raymond James	Lower Target	Outperform	$65.00 ➝ $60.00	Medium
11/2/2020	Robert W. Baird	Initiated Coverage	Underperform	$14.00	High
10/13/2020	Morgan Stanley	Lower Target	Equal Weight	$32.00 ➝ $31.00	Medium
8/10/2020	Morgan Stanley	Boost Target	Equal Weight	$27.00 ➝ $32.00	Low
8/7/2020	Raymond James	Boost Target	Outperform	$46.00 ➝ $65.00	High
6/18/2020	SunTrust Banks	Initiated Coverage	Buy	$45.00	High
6/15/2020	Oppenheimer	Reiterated Rating	Hold		High
6/12/2020	Chardan Capital	Reiterated Rating	Buy	$55.00	High
5/11/2020	Morgan Stanley	Lower Target	Equal Weight	$30.00 ➝ $27.00	High
5/7/2020	Oppenheimer	Initiated Coverage	Hold		Medium
3/4/2020	Chardan Capital	Reiterated Rating	Buy	$55.00	High
2/27/2020	Raymond James	Lower Target	Outperform	$44.00 ➝ $41.00	High
2/27/2020	JPMorgan Chase & Co.	Reiterated Rating	Hold		High
2/21/2020	Wells Fargo & Company	Initiated Coverage	Equal Weight	$28.00	High
12/10/2019	Chardan Capital	Reiterated Rating	Buy	$55.00	Low
8/9/2019	Morgan Stanley	Set Target	Hold	$29.00	High
7/25/2019	Chardan Capital	Reiterated Rating	Buy	$55.00	Medium
6/16/2019	Chardan Capital	Set Target	Buy	$55.00	Medium
5/8/2019	Oppenheimer	Reiterated Rating	Hold		Medium

(Data available from 4/20/2019 forward)

News Sentiment Rating

1.00 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

3 very positive mentions
5 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/23/2023

2 very positive mentions
9 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/23/2023

4 very positive mentions
12 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

11/22/2023

4 very positive mentions
7 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

12/22/2023

8 very positive mentions
9 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

1/21/2024

2 very positive mentions
6 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/20/2024

11 very positive mentions
18 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/21/2024

5 very positive mentions
2 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

4/20/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Today's Range

Now: $5.49

$5.29

$5.68

50 Day Range

MA: $7.78

$5.49

$11.07

52 Week Range

Now: $5.49

$5.28

$11.91

Volume

2,264,535 shs

Average Volume

1,537,266 shs

Market Capitalization

$451.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Editas Medicine?: The following Wall Street analysts have issued reports on Editas Medicine in the last year: Barclays PLC, Cantor Fitzgerald, Chardan Capital, Citigroup Inc., JPMorgan Chase & Co., Oppenheimer Holdings Inc., Raymond James, Stifel Nicolaus, StockNews.com, and Truist Financial Co..
View the latest analyst ratings for EDIT.
What is the current price target for Editas Medicine?: 9 Wall Street analysts have set twelve-month price targets for Editas Medicine in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 173.2%. Truist Financial Co. has the highest price target set, predicting EDIT will reach $20.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $9.00 for Editas Medicine in the next year.
View the latest price targets for EDIT.
What is the current consensus analyst rating for Editas Medicine?: Editas Medicine currently has 4 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for EDIT.
What other companies compete with Editas Medicine?: Other companies that are similar to Editas Medicine include Taysha Gene Therapies, C4 Therapeutics, Tourmaline Bio, Alector and Exscientia. Learn More about companies similar to Editas Medicine.
How do I contact Editas Medicine's investor relations team?: Editas Medicine's physical mailing address is 11 Hurley Street, Cambridge MA, 02141. The company's listed phone number is (617) 401-9000 and its investor relations email address is [email protected]. The official website for Editas Medicine is www.editasmedicine.com. Learn More about contacing Editas Medicine investor relations.

Editas Medicine - EDIT Stock Price Target and Predictions

Analyst Price Target for EDIT

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

1.00 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Editas Medicine?

What is the current price target for Editas Medicine?

What is the current consensus analyst rating for Editas Medicine?

What other companies compete with Editas Medicine?

How do I contact Editas Medicine's investor relations team?